State Street(R) SPDR(R) S&P(R) Biotech ETF (XBI)
- Fund company
- SPDR Series Trust
- Fund net assets
- $10.7B
- Equity lines
- 150
- Holdings as of
- 30 June 2026
- Source
- N-PORT report, SEC →
Weighted score of the companies held
So far, 9% of the fund is scored by Scorvest. The score is published once more than 50% is: the missing companies are being added.
–
- Profitability
- –
- Balance sheet
- –
- Cash generation
- –
- Stability
- –
- Growth
- –
Fund split by score
- Scored 75+ 2%
- Scored 40–74 3%
- Scored below 40 4%
- Not scored yet 91%
Sectors
Countries
Top holdings
| Company | Weight | Score | |
|---|---|---|---|
| Apogee Therapeutics Inc | 1.49% | pending | |
| Moderna, Inc. | 1.41% | 30 | |
| Twist Bioscience Corp | 1.41% | pending | |
| Oruka Therapeutics Inc | 1.38% | pending | |
| Kymera Therapeutics Inc | 1.36% | pending | |
| Viking Therapeutics Inc | 1.30% | pending | |
| Praxis Precision Medicines Inc | 1.29% | pending | |
| Erasca Inc | 1.27% | pending | |
| Revolution Medicines, Inc. | 1.20% | 9 | |
| Rhythm Pharmaceuticals Inc | 1.20% | pending | |
The next 40 holdings are visible from the Essential plan. Try free for 7 days → | |||
Computed from the equity lines reported by the fund. Weights are those of the N-PORT report at the date shown. General information, not investment advice.